AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
InflaRx shares jump 20.87% intraday after Raymond James and Cantor Fitzgerald raise price targets on positive HS trial data.
ByAinvest
Tuesday, Nov 11, 2025 11:43 am ET1min read
InflaRx surged 20.87% intraday after Raymond James and Cantor Fitzgerald raised price targets to $9 and $8, respectively, following strong Phase 2a data for INF904 in hidradenitis suppurativa (HS) patients. The trial showed a 63% HiSCR50 response rate at Week 8 for the 120mg BID dose, with notable reductions in abscesses and pain, outperforming competitor Phase 3 results. Raymond James cited the data as a "strong foundation" for HS and complement-driven autoimmune disease programs, while Cantor Fitzgerald upgraded its rating to Overweight. The news, coupled with H.C. Wainwright’s initiation of coverage at a $6 price target, fueled investor optimism amid the company’s upcoming Q3 2025 earnings report on November 10.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet